Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Locally Advanced or Unresectable Metastatic Breast Cancer|Stage IV Breast Cancer
Interventions: DRUG: Sacituzumab Govitecan-hziy|DRUG: Paclitaxel|DRUG: Nab-paclitaxel|DRUG: Capecitabine
Sponsor: Gilead Sciences